Bookmark
Forward
In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
Annals of internal medicine 2021 JanSizes of these terms reflect their relevance to your search.
RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345-52. 33031764.
Citation
Ameeta Singh. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days. Annals of internal medicine. 2021 Jan;174(1):JC3
Mesh Tags
Substances
PMID: 33395331
View Full Text
